Behavioural Intervention
Mega Team - video game for ADHD, ASD, and CHD
Recruiting1 award14 criteria
Toronto, Ontario
This trial tests a video game called Mega Team designed to help children aged 6-12 with ADHD, ASD, or CHD improve their thinking skills. The game gets harder as they play, helping them practice memory and self-control. Children will play the game at home, and their progress will be monitored by research staff.
Behavioural Intervention
Cognitive Training for ADHD
Recruiting1 award
Tallahassee, Florida
This trial is testing a new computer program called Central Executive Training (CET) to help kids with ADHD improve their memory and attention. The program uses fun computer games to practice these skills. It was developed with input from experts, caregivers, and kids with ADHD. Central Executive Training (CET) has been shown to improve executive function deficits and behavioral symptoms in children with ADHD.
Stimulant
Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine +1 More for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awards8 criteria
Montreal, Quebec
The purpose of this project is to evaluate the effectiveness of a structured aerobic exercise intervention for adults with Attention-Deficit/Hyperactivity Disorder (ADHD) with and without medication and compare it to medication alone. Participants will be randomly assigned to medication only + education, aerobic exercise intervention only, and combined aerobic exercise and medication groups. Participants will be evaluated at baseline, following medication optimization (for medicated groups), following 8 weeks of intervention, after 3 months of follow-up, and after 6 months of follow-up. The investigators hypothesize that the combined group will have the best outcome at all evaluation points and that treatment gains will be maintained throughout the follow-up period if the assigned treatments are continued.
Popular Filters
Trials for Attention Deficit Hyperactivity Disorder (ADHD) Patients
Stimulant
Long-acting stimulant for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awards4 criteria
Montreal, Quebec
The purpose of the study is to examine how well two types of treatment follow up work compared to one another: 1. standard community follow up 2. medication monitoring plus tailored case management follow up. A child's participation will involve 3 months of treatment consisting of medication and psychological, behavioural, and academic interventions tailored to their individual needs. Following this treatment, the child will be randomly assigned to receive two years of either community follow up or medication monitoring plus tailored case management follow up delivered by the study team. During both types of follow up, at 6 month intervals, the parent and child will be asked to complete interviews with our study personnel and comprehensive assessments pertaining to ADHD symptoms and various other areas of functioning. Parents will also be asked to obtain information from the child's teacher regarding the child's functioning at 6 month intervals during the school year.
Behavioural Intervention
Cogmed Working Memory Training Program for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 awardPhase 1
Toronto, Ontario
The overall objective of the current study is to determine whether computerized Working Memory (WM) training will enhance WM capacity in college students with Attention Deficit Hyperactivity Disorder (ADHD). There are also four additional objectives. The first is to investigate whether the program's efficacy is impacted by the duration of the daily training sessions. The second is to determine whether improvements in WM will generalize to secondary outcome tasks, such as inhibitory control and planning. The third objective is to examine whether WM training will also ameliorate ADHD symptoms of inattention and hyperactivity. The last objective is to investigate whether improvements will be maintained at a two month follow-up period. The investigators will also be assessing healthy control participants,who will not be receiving treatment, but will be used as a basis of comparison with the ADHD participants, It is expected that the computerized WM training program will enhance WM capacity in college students with ADHD. In addition, it is believed that these increases in WM capacity will also lead to improvements in other executive functions. It is also hypothesized that WM training will lead to a reduction in ADHD symptomology. Lastly, these improvements should be maintained at three month follow-up.
Corticosteroid
Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awardsPhase 3
Cincinnati, Ohio
The purpose of this study is to find out if children with attention-deficit, hyperactivity disorder (ADHD) have a difference in how their brain cells "fire" or react. The investigators also want to find if brain cell "firing" can tell us how severe of symptoms a child has from ADHD. Finally, the investigators want to see if giving an ADHD medication called atomoxetine can make the ADHD symptoms in a child better and if the improvement shows a change in brain "firing".
Cognitive Training
Cognitive Remediation +1 More for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting0 awardsPhase 2
Flushing, New York
The objective of this study is to evaluate a novel sequenced combination of a promising, computerized cognitive training program targeting working memory (WM) deficits in children with attention-deficit/hyperactivity disorder (ADHD) in combination with behavioral parent training, a well-established, evidence-based intervention for ADHD. The combined active intervention, compared to the combined control intervention will result in improvement in primary psychosocial (i.e., parent/teacher reported child impairment; parental stress; parenting behavior; and observed child academic achievement) and psychiatric (parent/teacher rated ADHD, ODD, and CD symptoms; observed activity level and attention) outcomes at post-treatment and follow up assessment, with the combined active intervention resulting in greater improvements in these outcomes.
Behavioural Intervention
Behavioral contingency management +1 More for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 award2 criteria
Charlottesville, Virginia
This trial aims to help children with ADHD make friends by training teachers to highlight their positive behaviors. The goal is to reduce peer rejection by changing how classmates perceive these children. The intervention will be tested in a program similar to a regular classroom.
Behavioural Intervention
Shared Care for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 award7 criteria
Long Island City, New York
Due to the shortage of child psychiatrists and the high prevalence of child mental health disorder, pediatricians and other pediatric primary care providers often assume responsibility for the management of various psychiatric disorders, including ADHD, Attention Deficit Hyperactivity Disorder. However, pediatricians have not been well-trained during residency to deal with the complexities of ADHD management. In addition, the system of care under which pediatricians practice do not afford the time availability that is required to properly manage a child with ADHD. On the other hand, if a pediatrician wishes to refer a patient to a child mental health specialist, many obstacles, including but not limited to stigma, insurance issues, and long waiting lists, often interfere with the patient actually receiving services for his/her ADHD. This research project seeks to examine an innovative model of care in which a child psychologist is located on the premises of a pediatric office and is available to share the care of patients with the pediatrician in order to address ADHD. We hypothesize that parents as well as pediatricians will be more satisfied with this model of care and that patients will ultimately have better outcomes. The beginning of our pilot has shown under-identification to be a barrier to care as well, and thus we propose to implement a quality improvement initiative to screen children for psychosocial issues as well. As we have had trouble with recruitment and unfortunately have had more children randomized to TAU than shared care, we propose in December 2007 a phase 2 of our study where all subjects, instead of randomization, are entered into shared care.
Trials for Attention Deficit Disorder Patients
Stimulant
Long-acting stimulant for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awards4 criteria
Montreal, Quebec
The purpose of the study is to examine how well two types of treatment follow up work compared to one another: 1. standard community follow up 2. medication monitoring plus tailored case management follow up. A child's participation will involve 3 months of treatment consisting of medication and psychological, behavioural, and academic interventions tailored to their individual needs. Following this treatment, the child will be randomly assigned to receive two years of either community follow up or medication monitoring plus tailored case management follow up delivered by the study team. During both types of follow up, at 6 month intervals, the parent and child will be asked to complete interviews with our study personnel and comprehensive assessments pertaining to ADHD symptoms and various other areas of functioning. Parents will also be asked to obtain information from the child's teacher regarding the child's functioning at 6 month intervals during the school year.
Behavioural Intervention
Cogmed Working Memory Training Program for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 awardPhase 1
Toronto, Ontario
The overall objective of the current study is to determine whether computerized Working Memory (WM) training will enhance WM capacity in college students with Attention Deficit Hyperactivity Disorder (ADHD). There are also four additional objectives. The first is to investigate whether the program's efficacy is impacted by the duration of the daily training sessions. The second is to determine whether improvements in WM will generalize to secondary outcome tasks, such as inhibitory control and planning. The third objective is to examine whether WM training will also ameliorate ADHD symptoms of inattention and hyperactivity. The last objective is to investigate whether improvements will be maintained at a two month follow-up period. The investigators will also be assessing healthy control participants,who will not be receiving treatment, but will be used as a basis of comparison with the ADHD participants, It is expected that the computerized WM training program will enhance WM capacity in college students with ADHD. In addition, it is believed that these increases in WM capacity will also lead to improvements in other executive functions. It is also hypothesized that WM training will lead to a reduction in ADHD symptomology. Lastly, these improvements should be maintained at three month follow-up.
Corticosteroid
Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awardsPhase 3
Cincinnati, Ohio
The purpose of this study is to find out if children with attention-deficit, hyperactivity disorder (ADHD) have a difference in how their brain cells "fire" or react. The investigators also want to find if brain cell "firing" can tell us how severe of symptoms a child has from ADHD. Finally, the investigators want to see if giving an ADHD medication called atomoxetine can make the ADHD symptoms in a child better and if the improvement shows a change in brain "firing".
Cognitive Training
Cognitive Remediation +1 More for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting0 awardsPhase 2
Flushing, New York
The objective of this study is to evaluate a novel sequenced combination of a promising, computerized cognitive training program targeting working memory (WM) deficits in children with attention-deficit/hyperactivity disorder (ADHD) in combination with behavioral parent training, a well-established, evidence-based intervention for ADHD. The combined active intervention, compared to the combined control intervention will result in improvement in primary psychosocial (i.e., parent/teacher reported child impairment; parental stress; parenting behavior; and observed child academic achievement) and psychiatric (parent/teacher rated ADHD, ODD, and CD symptoms; observed activity level and attention) outcomes at post-treatment and follow up assessment, with the combined active intervention resulting in greater improvements in these outcomes.
Behavioural Intervention
Behavioral contingency management +1 More for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 award2 criteria
Charlottesville, Virginia
This trial aims to help children with ADHD make friends by training teachers to highlight their positive behaviors. The goal is to reduce peer rejection by changing how classmates perceive these children. The intervention will be tested in a program similar to a regular classroom.
Behavioural Intervention
Shared Care for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 award7 criteria
Long Island City, New York
Due to the shortage of child psychiatrists and the high prevalence of child mental health disorder, pediatricians and other pediatric primary care providers often assume responsibility for the management of various psychiatric disorders, including ADHD, Attention Deficit Hyperactivity Disorder. However, pediatricians have not been well-trained during residency to deal with the complexities of ADHD management. In addition, the system of care under which pediatricians practice do not afford the time availability that is required to properly manage a child with ADHD. On the other hand, if a pediatrician wishes to refer a patient to a child mental health specialist, many obstacles, including but not limited to stigma, insurance issues, and long waiting lists, often interfere with the patient actually receiving services for his/her ADHD. This research project seeks to examine an innovative model of care in which a child psychologist is located on the premises of a pediatric office and is available to share the care of patients with the pediatrician in order to address ADHD. We hypothesize that parents as well as pediatricians will be more satisfied with this model of care and that patients will ultimately have better outcomes. The beginning of our pilot has shown under-identification to be a barrier to care as well, and thus we propose to implement a quality improvement initiative to screen children for psychosocial issues as well. As we have had trouble with recruitment and unfortunately have had more children randomized to TAU than shared care, we propose in December 2007 a phase 2 of our study where all subjects, instead of randomization, are entered into shared care.
Phase 3 Trials
Corticosteroid
Atomoxetine for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awardsPhase 3
Cincinnati, Ohio
The purpose of this study is to find out if children with attention-deficit, hyperactivity disorder (ADHD) have a difference in how their brain cells "fire" or react. The investigators also want to find if brain cell "firing" can tell us how severe of symptoms a child has from ADHD. Finally, the investigators want to see if giving an ADHD medication called atomoxetine can make the ADHD symptoms in a child better and if the improvement shows a change in brain "firing".
Stimulant
ADHD Medication + Parent Training for ADHD Families
Recruiting4 awardsPhase 3
College Park, Maryland
This trial will compare the effectiveness of treating ADHD in children when their parent also has ADHD, versus treating the child's ADHD alone. They will also study the parents' ADHD symptoms and how well they are able to engage in parent training.
Norepinephrine-Dopamine Reuptake Inhibitor
Centanafadine for ADHD
Recruiting2 awardsPhase 3
New York, New York
This trial aims to test the safety and tolerability of a daily ADHD medication in children and teens aged 4-17. The medication releases its effects slowly over the day to help manage symptoms consistently. HLD200 is a form of methylphenidate designed to provide benefits from morning until evening.
Norepinephrine-Dopamine Reuptake Inhibitor
Centanafadine for ADHD
Recruiting1 awardPhase 3
New York, New York
This trial will test if centanafadine, a daily extended-release medication, can help children aged 4 to 12 years with ADHD by balancing brain chemicals to improve focus and reduce hyperactivity. Centanafadine is being investigated for the treatment of ADHD.
Behavioural Intervention
Solriamfetol for ADHD
Recruiting1 awardPhase 3
Orlando, Florida
This trial is testing solriamfetol, a medication that may help adults with ADHD by balancing brain chemicals that control focus and activity levels. Participants will take solriamfetol once daily for several weeks to see if it improves their symptoms. Solriamfetol has been studied for its effectiveness in treating excessive sleepiness related to narcolepsy and obstructive sleep apnea, showing improvements in sleep latency and overall sleepiness scores.
Trials With No Placebo
Stimulant
Long-acting stimulant for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting3 awards4 criteria
Montreal, Quebec
The purpose of the study is to examine how well two types of treatment follow up work compared to one another: 1. standard community follow up 2. medication monitoring plus tailored case management follow up. A child's participation will involve 3 months of treatment consisting of medication and psychological, behavioural, and academic interventions tailored to their individual needs. Following this treatment, the child will be randomly assigned to receive two years of either community follow up or medication monitoring plus tailored case management follow up delivered by the study team. During both types of follow up, at 6 month intervals, the parent and child will be asked to complete interviews with our study personnel and comprehensive assessments pertaining to ADHD symptoms and various other areas of functioning. Parents will also be asked to obtain information from the child's teacher regarding the child's functioning at 6 month intervals during the school year.
Behavioural Intervention
Cogmed Working Memory Training Program for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 awardPhase 1
Toronto, Ontario
The overall objective of the current study is to determine whether computerized Working Memory (WM) training will enhance WM capacity in college students with Attention Deficit Hyperactivity Disorder (ADHD). There are also four additional objectives. The first is to investigate whether the program's efficacy is impacted by the duration of the daily training sessions. The second is to determine whether improvements in WM will generalize to secondary outcome tasks, such as inhibitory control and planning. The third objective is to examine whether WM training will also ameliorate ADHD symptoms of inattention and hyperactivity. The last objective is to investigate whether improvements will be maintained at a two month follow-up period. The investigators will also be assessing healthy control participants,who will not be receiving treatment, but will be used as a basis of comparison with the ADHD participants, It is expected that the computerized WM training program will enhance WM capacity in college students with ADHD. In addition, it is believed that these increases in WM capacity will also lead to improvements in other executive functions. It is also hypothesized that WM training will lead to a reduction in ADHD symptomology. Lastly, these improvements should be maintained at three month follow-up.
Behavioural Intervention
Behavioral contingency management +1 More for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 award2 criteria
Charlottesville, Virginia
This trial aims to help children with ADHD make friends by training teachers to highlight their positive behaviors. The goal is to reduce peer rejection by changing how classmates perceive these children. The intervention will be tested in a program similar to a regular classroom.
Behavioural Intervention
Shared Care for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting1 award7 criteria
Long Island City, New York
Due to the shortage of child psychiatrists and the high prevalence of child mental health disorder, pediatricians and other pediatric primary care providers often assume responsibility for the management of various psychiatric disorders, including ADHD, Attention Deficit Hyperactivity Disorder. However, pediatricians have not been well-trained during residency to deal with the complexities of ADHD management. In addition, the system of care under which pediatricians practice do not afford the time availability that is required to properly manage a child with ADHD. On the other hand, if a pediatrician wishes to refer a patient to a child mental health specialist, many obstacles, including but not limited to stigma, insurance issues, and long waiting lists, often interfere with the patient actually receiving services for his/her ADHD. This research project seeks to examine an innovative model of care in which a child psychologist is located on the premises of a pediatric office and is available to share the care of patients with the pediatrician in order to address ADHD. We hypothesize that parents as well as pediatricians will be more satisfied with this model of care and that patients will ultimately have better outcomes. The beginning of our pilot has shown under-identification to be a barrier to care as well, and thus we propose to implement a quality improvement initiative to screen children for psychosocial issues as well. As we have had trouble with recruitment and unfortunately have had more children randomized to TAU than shared care, we propose in December 2007 a phase 2 of our study where all subjects, instead of randomization, are entered into shared care.
Central Nervous System Stimulant
Methylphenidate Transdermal System for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting2 awards6 criteria
Charlottesville, Virginia
Among children, attention-deficit/hyperactivity disorder (ADHD) is associated with an increased risk for accidents, especially bicycle and pedestrian (Leibson 2001; Jensen 1988; DiScala 1998). Anywhere from 40% to 80% of children diagnosed with ADHD continue to display symptoms of the disorder into adolescence(Barkley 1990; Gittelman 1985). Adolescents with ADHD are also at an increased risk for driving-related accidents, being 2 to 4 times more likely to experience a motor vehicle accident (Barkley 1993; Barkley 1996; Cox 2000), 4 times as likely to be at fault in the accident (Barkley 1993), and over 3 times more likely to incur associated injuries as a result of the accident(Murphy 1996). Stimulant treatment with immediate-release methylphenidate (IR MPH) has been demonstrated to improve driving performance in adolescents with ADHD. Hypothesis to be Tested: * Main study: Just as stimulant medication improves simulation and on-road driving performance of ADHD teenagers, it is hypothesized that stimulant medication will improve routine driving performance. * Substudy - Extended wear (15 hours) of Daytrana will lead to safer driving late in the evening (22:00 and 01:00), when the most dangerous driving mishaps are most likely to occur, and the next morning at 09:00.
Behavioural Intervention
ADHD Interventions + Stimulant for ADHD
Recruiting5 awardsPhase 4
Miami, Florida
This trial tests different ways to help children with ADHD behave better in school. It starts with general classroom techniques, adds more focused help if needed, and uses advanced methods or medication if necessary. The study targets young children with ADHD who are not in special education or on medication. Medication has been extensively studied and shown to improve ADHD symptoms in children.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.
Introduction to adhd
What are the top hospitals conducting adhd research?
In the realm of ADHD research and clinical trials, several hospitals have emerged as key players in advancing our understanding and treatment of this condition. Massachusetts General Hospital, located in Boston, leads the way with six ongoing ADHD trials and an impressive track record of 33 completed studies since their initial foray into ADHD research in 2001. Across the Atlantic, Hassman Research Institute based in Berlin has become a vital hub for ADHD trials as well. Though relatively new to the field with just four active trials and six overall studies since 2019, their dedication is undeniable.
Meanwhile, Alivation Research LLC located in Lincoln stands out with four active ADHD trials currently underway alongside seven previously conducted ones from their first recorded trial back in 2015. In Cincinnati's medical landscape, another institution making significant strides is Cincinnati Children's Hospital Medical Center where they boast involvement in four ongoing clinical tests alongside seventeen accomplished investigations dating back earlier to2003.The Seattle Children's Hospital also plays a crucial role within this sphere; while conducting three active ADHD trials at present it’s indeed noteworthy that theirs can be traced all the way back solely over eleven years ago to2009.
These hospitals signify not only breakthroughs but hope towards providing effective solutions for individuals affected by Attention Deficit Hyperactivity Disorder (ADHD). The collective efforts displayed among these leading institutions demonstrate unwavering commitment to unlocking greater insights into this neurodevelopmental disorder which affects millions worldwide. With each study undertaken comes potential advancements that could shape improved management strategies and brighter futures for those living with ADHD
Which are the best cities for adhd clinical trials?
When it comes to ADHD clinical trials, several cities have emerged as key players in the research field. Las Vegas, Nevada leads the pack with 12 active trials focusing on treatments like SPN-812 and Guanfacine hydrochloride (TAK-503). New york, New York follows closely behind with 10 ongoing studies examining therapies for adult ADHD patients such as centanafadine capsule. Boston, Massachusetts has 9 active trials investigating interventions like SMS Intervention and Solriamfetol 150 mg. Additionally, Cincinnati, Ohio is conducting 8 trials exploring treatments including Atomoxetine and Guanfacine hydrochloride (TAK-503), while Jacksonville, Florida offers 7 trials studying various ADHD therapies. These cities provide individuals with ADHD opportunities to participate in cutting-edge clinical research that could drive advancements in treatment options and improve quality of life.
Which are the top treatments for adhd being explored in clinical trials?
Exciting advancements are being made in the exploration of top treatments for ADHD through ongoing clinical trials. One notable intervention is SMS Intervention, which is currently being tested in three active trials and has a total of three ADHD trials since its initial listing in 2016. Additionally, there are two active trials investigating the effectiveness of ADHD Therapy, a treatment that entered the scene in 2023. Another intriguing avenue being explored is Tai Chi, with two active trials underway since its introduction to ADHD research in 2016. Finally, it's worth mentioning methylphenidate—a well-established player—which continues to show promise with two ongoing studies and an impressive track record of forty all-time ADHD trials dating back to 1998. As researchers delve deeper into these approaches, new possibilities may emerge for individuals affected by ADHD.
What are the most recent clinical trials for adhd?
Recent clinical trials have provided promising prospects for individuals with ADHD, offering potential advancements in treatment and care. Among these trials is the exploration of an experimental medication called CTx-1301, specifically a 37.5mg dexmethylphenidate tablet. The study aims to evaluate its efficacy in managing symptoms associated with ADHD, bringing hope to those seeking effective pharmaceutical interventions. Furthermore, another trial investigates the use of solriamfetol at a dose of 150 mg as a potential treatment option for ADHD patients. By delving into these innovative approaches through rigorous phases of testing, researchers aim to improve the lives and well-being of individuals living with this condition.
What adhd clinical trials were recently completed?
In the realm of ADHD research, recent clinical trials have reached significant milestones, bringing us closer to improved treatments for this neurodevelopmental disorder. In August 2021, Massachusetts General Hospital successfully completed a trial investigating the effectiveness of Solriamfetol 75 MG in managing ADHD symptoms. Similarly, Otsuka Pharmaceutical Development & Commercialization accomplished a trial testing Centanafadine in March 2021. These advancements highlight the commitment of researchers to finding novel solutions for individuals with ADHD and hold promise for enhancing their quality of life.